Latest Breaking News On - Qure forward looking - Page 11 : vimarsana.com

uniQure Inc : uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington s Disease

~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2021.

Noord hollandChiara russoDavid cooperMariae cantorTom malonePhasei ii clinical programFirst four patients enrolledHigher dose cohortEnrollment expectedQure forward lookingAnnual reportQuarterly reportQure contacts

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinic

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinic
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Noord hollandChiara russoDavid cooperMariae cantorTom malonePhasei ii clinical programQure announces completionData safety monitoring boardFull study enrollment expectedQure forward lookingAnnual reportQuarterly reportQure contacts

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.

Noord hollandChiara russoPierre calozChristian klemtMariae cantorMatt kapustaTom maloneDevelopment dayResearch development dayFrench ministry of economyCompany progressQure announces second quarterHighlights recent companyCorlieve therapeuticsEuropean phaseHart scott rodino antitrust improvements act

uniQure Inc : uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington s Disease

uniQure Inc : uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington s Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandChiara russoRicardo dolmetschMariae cantorTom malonePhasei ii clinical programData safety monitoring boardQure forward lookingLicense agreementAnnual reportQuarterly reportQure contactsஒன்றுபட்டது மாநிலங்களில்நூற்த் ஹாலண்ட்சியாரா ருஸ்ஸோ

uniQure Inc : uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington s Disease

(1) Independent Data Safety Monitoring Board Recommends Proceeding with Second, Higher-Dose Cohort LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021has met and reviewed safety data for the fully enrolled first cohort of ten patients. This data set included nine-month safety data from the first two enrolled patients, six-month safety data from the next two enrolled patients, and 30-day safety data on remaining six patients in the trial. The DSMB recommended continued dosing in the study, and uniQure will now begin to enroll patients in the higher-dose cohort of the trial. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States. To date, six patients have been treated with AMT-130, and four patients received the imitation surgery.

United statesNoord hollandChiara russoRicardo dolmetschMariae cantorTom malonePhasei ii clinical programQure forward lookingLicense agreementAnnual reportQuarterly reportQure contactsஒன்றுபட்டது மாநிலங்களில்நூற்த் ஹாலண்ட்சியாரா ருஸ்ஸோடோம் மலோந்